Janux Therapeutics Inc (JANX)

$47.10 0.41 (0.86%)

16:00 EDT JANX Stock Quote Delayed 30 Minutes

JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 7, 2024

JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Take the Money and Run: 3 Overbought Stocks to Sell ASAP

These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?

JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 698,030

Day's Range $46.79 - $47.97

52-Week Range $5.65 - $65.60

Dividend & Yield N/A (N/A)

JANX Stock Predictions, Articles, and Janux Therapeutics Inc News

From InvestorPlace
From the Web

Why Is Janux Therapeutics (JANX) Stock Up 108% Today?

By William White, InvestorPlace Writer Feb 27, 2024

Janux Therapeutics stock is rocketing higher on Tuesday after the company provided JANX shareholders with clinical trial updates.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Feb 27, 2024

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news affecting shares on Tuesday morning!

7 Biotech Stocks That Could Be the Next Big Thing

By Josh Enomoto, InvestorPlace Contributor Mar 15, 2023

Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.

7 Short-Squeeze Stocks for Bold Contrarians to Consider

By Josh Enomoto, InvestorPlace Contributor Nov 21, 2022

While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists.

7 Short-Squeeze Stocks to Buy for Contrarian Investors

By Josh Enomoto, InvestorPlace Contributor Oct 12, 2022

Although a terribly risky venture, these short-squeeze stocks feature intense bearishness that may have gone overboard.

Why Janux Therapeutics Stock Is Crushing It This Week

From The Motley Fool Apr 12, 2024

Janux's silence about a potential acquisition deal could be golden.

Why Janux Therapeutics Stock Soared as the Market Sagged Today

From The Motley Fool Apr 10, 2024

One of the hotter biotech companies on the scene might be changing owners before long.

Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale

From Bloomberg Apr 10, 2024

Drugmaker Janux Therapeutics Inc. is exploring options, including a potential sale, after receiving takeover interest from larger pharmaceutical companies, people with knowledge of the matter said.

2 Stocks That Have More Than Tripled This Year: Are They Buys?

From The Motley Fool Mar 15, 2024

Don't jump on the bandwaggon too quickly.

After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?

From The Motley Fool Mar 2, 2024

The biotech tantalized investors with a very promising data update.

Janux Therapeutics prices stock and warrants offering to raise $296.5M (NASDAQ:JANX)

From Seeking Alpha Feb 29, 2024

Janux Therapeutics (NASDAQ:JANX) said Thursday it has priced an underwritten public offering to raise $296.5 million.

ADVERTISEMENT